Other OTC - Delayed Quote • USD
Appili Therapeutics Inc. (APLIF)
As of 9:30 AM EDT. Market Open.
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Donald D. Cilla Jr., M.B.A., Pharmd | CEO, President & Director | 414.5k | -- | -- |
| Mr. Kenneth G. Howling | Chief Financial Officer | 381.2k | -- | -- |
| Dr. Gary S. Nabors Ph.D. | Chief Development Officer | -- | -- | -- |
Appili Therapeutics Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 8
Description
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.
Corporate Governance
Appili Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
Recent Events Information Not Available
Upcoming Events
Jun 21, 2024 - Jun 25, 2024
Appili Therapeutics Inc. Earnings Call
Related Tickers
ADTX Aditxt, Inc.
2.4400
-3.56%
IVBXF Innovent Biologics, Inc.
4.8900
0.00%
XSNX NovAccess Global Inc.
0.0051
0.00%
ACOGF Alpha Cognition Inc.
0.4950
0.00%
RVLPQ RVL Pharmaceuticals plc
0.0000
0.00%
RGRX RegeneRx Biopharmaceuticals, Inc.
0.0014
0.00%
GBLX GB Sciences, Inc.
0.0068
+8.28%
OTLC Oncotelic Therapeutics, Inc.
0.0408
0.00%
IGX.TO IntelGenx Technologies Corp.
0.2250
+21.62%
IGXT IntelGenx Technologies Corp.
0.1606
-3.45%